Gufic Biosciences (509079) Q2 24/25 earnings summary

Executive summary

• Indore facility commissioned and fully operational, expanding manufacturing capacity and regulatory reach for domestic and international markets, including US and EU.

• Strategic business units expanded, including Critical Care, Ferticare, Aesthaderm, Neuro Care, Sparsh, Spark, Stellar, and Healthcare, each targeting specific therapeutic areas and market needs.

• International business growth driven by new market approvals in Thailand, Sri Lanka, Cambodia, Lithuania, and a significant NHS UK tender win.

• Revenue from operations for H1 FY25 was ₹40,699.19 lakhs (standalone) and ₹40,836.03 lakhs (consolidated), showing stable performance year-over-year.

• Net profit for H1 FY25 was ₹4,263.44 lakhs (standalone) and ₹4,383.25 lakhs (consolidated), reflecting consistent profitability.

Financial highlights

• Q2 FY25 revenue at INR 204.2 crore, down from INR 214.9 crore in Q2 FY24.

• H1 FY25 revenue at INR 407 crore, nearly flat compared to INR 409.9 crore in H1 FY24.

• H1 FY25 EBITDA at INR 79.8 crore, up from INR 76.1 crore; EBITDA margin at 18.62%.

• H1 FY25 PAT at INR 42.6 crore, with a PAT margin of 10.47%.

• Cash generated from operations for H1 FY25 was ₹8,940.77 lakhs, a significant increase from ₹1,229.55 lakhs year-over-year.

Outlook and guidance

• Indore facility expected to contribute minimally to revenue in FY25, with significant impact anticipated over the next two to three years.

• EU and US regulatory approvals targeted, with EU audit expected by late 2024 and USFDA action anticipated in 2026.

• CMO/CDMO business to commence in late 2024, supporting long-term international growth.

• Focus on expanding contract manufacturing, entering new therapy areas, and continued investment in international registrations and high-value tenders.